Pierre Meulien has been appointed as president and CEO of Genome Canada, replacing Dale Patterson, who served as interim president and CEO and will remain vice president of external relations. Meulien joins the organization from Genome BC, where he was chief scientific officer. Previously, he was senior vice president of R&D at Aventis Pasteur in Toronto and director of research at Aventis Pasteur in Lyon. Prior to that, he was a research scientist and part of the management team of Transgene, a French biotechnology company. Meulien holds a PhD from the University of Edinburgh.
Paul Ventura has become director of sales at Sage Science. Previously, he was director of North American sales at Covaris.
Mary-Claire King has been elected as president of the American Society of Human Genetics, starting her tenure in 2012 after serving as president-elect for one year. She is a professor of genome sciences and medical genetics at the University of Washington. King, who discovered the BRCA1 breast cancer risk gene, holds a PhD in genetics from the University of California at Berkeley and a BA in mathematics from Carleton College.
David Gelfand has joined the newly created scientific advisory board of Signal Genetics, the parent company of Myeloma Health, a predictive genetic testing company that focuses on oncology. He is the chief scientific officer of WaferGen Biosystems. Previously, he held posts at Roche Molecular Systems, where he helped develop designer DNA polymerases, and at Cetus, where he helped pioneer PCR. Gelfand holds a PhD in biology from the University of California, San Diego.
Joan Cronin has become senior vice president and chief people officer of Saba, a new position. Most recently, she was vice president and chief talent officer at Life Technologies and prior to that, vice president of human resources at Applied Biosystems. Cronin holds BA and MA degrees from the University of Puget Sound.